Raymond James analyst Danielle Brill resumes coverage on PTC Therapeutics (NASDAQ: PTCT) with a Market Perform rating.The analyst comments "PTCT ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE